DOCSLIB.ORG

Monthly Dose March 2019 Monthly Dose July 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Monthly Dose March 2019 Monthly Dose July 2021 MONTHLY DOSE MARCHJULY 2021 2019 News for the Month Zydus Cadila applies for emergency use nod for Covid-19 vaccine Alembic Pharma gets USFDA nod for generic Nitrofurantoin capsules Zydus Cadila gets USFDA nod to market generic HIV infection treatment tablets Laurus Labs receives licence from DRDO to manufacture and market Covid drug 2DG Cadila Healthcare arm recalls 21,240 bottles of diabetes drug in US Torrent’s nasal spray exempted from price cap for five years Morepen Labs starts production of test batch of Sputnik V vaccine Dr. Reddy's bullish on OTC products sale through Amazon, others in US Glenmark to conduct Phase III trial nasal spray meant to treat Covid-19 Alembic Pharma gets USFDA nod for cancer treatment drug FDC launches Favipiravir oral suspension to treat Covid-19 in India SII to begin manufacturing Sputnik V vaccine in September, announces RDIF Lupin launches generic antifungal product in US market Zydus Cadila seeks approval for its needle-free Covid vaccine ZyCOV-D Cadila arm completes sale of animal health business for Rs2,921cr Company Venus Remedies launches consumer healthcare division USFDA issues import alert on Jubilant Pharmova's Roorkee plant Alkem looks for partnerships, in-licensing deals to bolster presence in US market Steriline Supplies Shilpa Medicare with Pilot Line for injectable oncology drugs EMA grants Orphan Drug Designation to Cadila's Saroglitazar Mg for treating patients with PBC Zydus Cadila gets tentative nod from USFDA to market cancer drug Bharat Biotech commits to supply 500 million doses of Covaxin to Centre for immunisation programme Biocon Biologics gets licence from Adagio Therapeutics for antibody treatment of Covid-19 BDR Pharma inks license agreement with DRDO to produce Covid-19 drug 2-DG Sun Pharma, Cassiopea SpA ink license & supply agreements for acne treatment drug Winlevi Made in India Sputnik V to be available during September-October: Dr. Reddy's Shilpa Medicare receives WHO approval for HIV drug Alkem Laboratories’ USFDA inspection at Taloja facility ends with 'zero' observations Biocon Biologics interchangeable insulin Semglee gets USFDA approval Local firms got voluntary license for more drugs during pandemic Revenue growth of drug firms in current fiscal to be in the range of 7-9%: Icra NPPA approves price rise of 50% for carbamazepine, ranitidine, ibuprofen India's most purchased drugs in the last decade are for cardiac ailments, diabetes Remdesivir, hydroxychloroquine show no antiviral effect against Covid-19: Study Industry Govt exempts raw material imports of Amphotericin B and Covid testing kits till September end Pfizer and BioNTech announce collaboration with Biovac to manufacture and distribute Covid-19 vaccine doses within Africa Global Vabiotech confirms production of first batch of Sputnik V vaccine in Vietnam Source: Media Reports and Company Press Releases Tentative ANDA Approvals: Company API Strengths Indications Brand (Company) Mkt Size Unichem Sitagliptin 25/50/100mg Indicated as an adjunct to diet and Januvia (Merck Sharpe and - Tablets exercise to improve glycemic Dohme Corp) control in adults with type 2 diabetes mellitus Cadila Ibrutinib Tablets 140/280/420/560mg Used to treat certain cancers Imbruvica Tablets (AbbVie USD3.7bn (annual Company) sales, Dec 2020) Source: Media Reports and Company Press Releases Final ANDA Approvals: Company API Strengths Indications Brand (Company) Mkt Size Alembic Nitrofurantoin 25/100mg Indicated for the treatment of Macrodantin Capsules USD23mn Capsules urinary tract infections (Alvogen Malta Operations Ltd) Alembic Erlotinib Tablets 25/100/150mg Used in the treatment of cancer Tarceva Tablets (OSI USD37mn Pharmaceuticals, LLC.) Caplin Point Sumatriptan Injection 6mg/0.5mL (12mg/ Indicated in adults for acute IMITREX Injection USD5mn mL) Single dose treatment of migraine with or (GlaxoSmithKline, USA.) (annual sales) Vials without aura, and acute treatment of cluster headache Cadila Fulvestrant Injection 250mg/5mL Used alone or in combination with Faslodex Injection USD407mn (50mg/mL) per other drugs to treat a certain type of (AstraZeneca) (annual sales, single-dose hormone receptor positive June, 2020) pre-filled syringe Source: Media Reports and Company Press Releases BSE Health Care Index Price Performance BSE Health Care Index Price Performance Change Change Companies Price Companies Price 1 M 6 M 12 M 1 M 6 M 12 M Aarti Drugs Ltd 668 -5.6% -0.9% -60.9% IPCA Laboratories Ltd 2102 3.8% 13.4% 20.5% Abbott India Ltd 19086 13.6% 34.0% 28.1% J.B.Chemicals & Pharma Ltd. 1812 9.0% 81.1% 149.4% Ajanta Pharma Ltd 2289 6.7% 29.5% 51.4% Laurus Labs Ltd 641 -5.7% 85.6% -19.0% Albert David Ltd 546 11.6% 28.2% 35.9% Lincoln Pharmaceuticals Ltd 349 -0.9% 56.5% 77.4% Alembic Ltd 121 -4.4% 28.5% 52.8% Lupin Ltd 1107 -3.7% 9.9% 24.4% Alembic Pharmaceuticals Ltd 788 -19.9% -17.3% -20.1% Marksans Pharma Ltd 82 -5.1% 48.8% 116.5% Alkem Laboratories Ltd 3455 8.1% 15.0% 35.7% Max Healthcare Institute Ltd 297 16.9% 83.3% - Apollo Hospitals Enterprise Ltd 4034 11.5% 57.5% 135.1% Metropolis Healthcare Ltd 2845 0.7% 38.0% 78.3% Aster DM Healthcare Ltd 163 5.8% 3.1% 24.5% Morepen Laboratories Ltd 65 4.1% 135.9% 198.4% AstraZeneca Pharma India 3371 -6.6% -7.2% 1.7% Narayana Hrudayalaya Ltd 490 -0.3% 10.3% 66.5% Aurobindo Pharma Ltd 917 -5.0% 1.2% 11.8% Natco Pharma Ltd 1024 -9.3% 14.7% 36.7% Biocon Ltd 387 -4.4% 3.9% -4.2% Neuland Laboratories Ltd 1986 -7.3% 54.4% 187.8% Bliss GVS Pharma Ltd 108 0.8% -42.0% 1.4% Novartis India Ltd 959 11.3% 46.6% 56.2% Cadila Healthcare Ltd 586 -9.2% 29.8% 60.3% Panacea Biotec Ltd 321 -13.1% 65.9% 63.5% Caplin Point Laboratories Ltd 884 32.7% 92.2% 116.8% Pfizer Ltd (India) 5871 3.5% 26.6% 38.7% Cipla Ltd 920 -5.3% 11.5% 34.2% Poly Medicure Ltd 982 -3.4% 93.9% 149.3% Dishman Carbogen Amics Ltd 209 -1.9% 70.4% 11.6% Procter & Gamble Health Ltd 5356 -4.3% -24.7% 28.9% Divi's Laboratories Ltd 4905 11.3% 45.5% 91.5% RPG Life Sciences Ltd 509 12.9% 26.3% 60.7% Dr. Reddy's Laboratories Ltd 4713 -13.1% 2.5% 4.4% Sanofi India Ltd 8368 8.8% 6.9% 8.8% Dr. Lal PathLabs Ltd 3555 8.6% 58.2% 89.0% Sequent Scientific Ltd 294 -6.0% 40.1% 152.2% Eris Lifesciences Ltd 792 11.9% 30.9% 68.8% Shalby Ltd 194 7.4% 79.3% 163.2% FDC Ltd 372 5.4% 28.6% 29.2% Shilpa Medicare Ltd 632 17.2% 49.8% 25.0% Fermenta Biotech Ltd 313 -2.9% 5.6% 8.5% Solara Active Pharma Sciences Ltd 1645 -2.1% 10.7% 150.7% Fortis Healthcare Ltd 251 3.0% 55.1% 80.9% Strides Pharma Science Ltd 770 1.4% -5.4% 83.0% Gland Pharma Ltd 3948 15.5% 86.5% - SPARC Ltd 270 17.4% 51.2% 54.8% GSK Pharmaceuticals Ltd 1608 7.0% 9.8% 11.4% Sun Pharmaceutical Industries Ltd 774 14.6% 32.0% 51.8% Glenmark Pharmaceuticals Ltd 608 -6.9% 28.6% 37.6% Suven Life Sciences Ltd 82 -6.3% 16.5% 122.1% Granules India Ltd 379 14.1% 12.5% 36.4% Suven Pharmaceuticals Ltd 509 5.8% 10.2% -14.7% Gufic Biosciences Ltd 184 -2.0% 55.9% 103.5% Syngene International Ltd 639 9.7% 12.9% 35.4% HealthCare Global Enterprises Ltd 250 11.8% 65.0% 100.0% Take Solutions Ltd 63 0.4% 15.9% 55.5% Hester Biosciences Ltd 2365 -8.9% 40.7% 79.3% Thyrocare Technologies Ltd 1308 -0.4% 44.9% 91.6% Hikal Ltd 535 9.0% 213.0% 262.9% Torrent Pharmaceuticals Ltd 3070 5.8% 17.9% 26.0% Indoco Remedies Ltd 450 8.8% 49.7% 110.5% Unichem Laboratories Ltd 333 4.7% 15.1% 55.8% Indraprastha Medical Corp. Ltd 83 -1.8% 56.4% 37.0% Vimta Labs Ltd 324 22.1% 90.7% 232.3% IOL Chemicals and Pharma Ltd 664 9.3% -1.9% -11.7% Wockhardt Ltd 530 2.3% 10.2% 101.4% Source: BSE website; Source: BSE website; All prices are as on 30th July 2021 All prices are as on 30th July 2021 NIFTY PHARMA COMPANIES Price Mcap Change Company (Rs) (Rsmn) 1 M 6 M 12 M Aurobindo Pharma Ltd. 917 537218 -5.01% 1.2% 11.8% Biocon Ltd. 387 463860 -4.4% 3.9% -4.2% Cadila Healthcare Ltd. 586 599862 -9.2% 29.8% 60.3% Cipla Ltd. 920 742311 -5.3% 11.5% 34.2% Divi's Laboratories Ltd. 4905 1302030 11.3% 45.5% 91.5% Dr. Reddy's Laboratories Ltd. 4713 784005 -13.1% 2.5% 4.4% Alkem Laboratories Ltd. 3455 413043 8.1% 15.0% 35.7% Lupin Ltd. 1107 502538 -3.7% 9.86% 24.4% Torrent Pharmaceuticals Ltd. 3070 519463 5.8% 17.88% 26.0% Sun Pharmaceutical Industries Ltd. 774 1857085 14.6% 32.0% 51.8% Source: NSE website, Company Research; All prices are as on 30th July 2021 Nifty Pharma Index Vs. Nifty Index Source: NSE website DISCLAIMERS AND DISCLOSURES- Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India.
Load more

Recommended publications
  • Loan Against Securities – Approved Single Scrips
    Loan against securities – Approved Single Scrips SR no ISIN Scrip Name Margin 1 INE216A01030 BRITANNIA INDUSTRIES LIMITED 50 2 INE854D01024 UNITED SPIRITS LIMITED 50 3 INE437A01024 APOLLO HOSPITALS ENTERPRISE LTD 50 4 INE208A01029 ASHOK LEYLAND LTD 50 5 INE021A01026 ASIAN PAINTS LTD 50 6 INE406A01037 AUROBINDO PHARMA LTD 50 7 INE917I01010 BAJAJ AUTO LTD 50 8 INE028A01039 BANK OF BARODA 50 9 INE084A01016 BANK OF INDIA 50 10 INE463A01038 BERGER PAINTS INDIA LTD 50 11 INE029A01011 BHARAT PETROLEUM CORPORATION LTD 50 12 INE323A01026 BOSCH LTD 50 13 INE010B01027 CADILA HEALTHCARE LTD 50 14 INE059A01026 CIPLA LTD 50 15 INE522F01014 COAL INDIA LTD 50 16 INE259A01022 COLGATE-PALMOLIVE (INDIA) LTD 50 17 INE361B01024 DIVIS LABORATORIES LTD 50 18 INE089A01023 DRREDDYS LABORATORIES LTD 50 19 INE129A01019 GAIL (INDIA) LTD 50 20 INE860A01027 HCL TECHNOLOGIES LTD 50 21 INE158A01026 HERO MOTOCORP LTD 50 22 INE038A01020 HINDALCO INDUSTRIES LTD 50 23 INE094A01015 HINDUSTAN PETROLEUM CORPORATION LTD 50 24 INE030A01027 HINDUSTAN UNILEVER LTD 50 25 INE079A01024 AMBUJA CEMENTS LTD 50 26 INE001A01036 HOUSING DEVELOPMENT FINANCE CORPLTD 50 27 INE090A01021 ICICI BANK LTD 50 28 INE242A01010 INDIAN OIL CORPORATION LTD 50 29 INE009A01021 INFOSYS LTD 50 30 INE154A01025 ITC LTD 50 31 INE237A01028 KOTAK MAHINDRA BANK LTD 50 32 INE498L01015 LT FINANCE HOLDINGS LTD 50 33 INE018A01030 LARSEN TOUBRO LTD 50 34 INE326A01037 LUPIN LTD 50 35 INE101A01026 MAHINDRA MAHINDRA LTD 50 36 INE585B01010 MARUTI SUZUKI INDIA LTD 50 37 INE775A01035 MOTHERSON SUMI SYSTEMS LTD 50 38 INE883A01011
    [Show full text]
  • Franklin India Fund LU1212701376 31 August 2021
    Franklin Templeton Investment Funds India Equity Franklin India Fund LU1212701376 31 August 2021 Fund Fact Sheet For Professional Client Use Only. Not for distribution to Retail Clients. Fund Overview Performance Base Currency for Fund USD Performance over 5 Years in Share Class Currency (%) Total Net Assets (USD) 1,44 billion Franklin India Fund A (acc) EUR-H1 MSCI India Index-NR in USD Fund Inception Date 25.10.2005 190 Number of Issuers 45 170 Benchmark MSCI India Index-NR 150 Morningstar Category™ Other Equity 130 Summary of Investment Objective The Fund aims to achieve long-term capital appreciation by 110 principally investing in equity securities of companies of any size located or performing business predominately in India. 90 Fund Management 70 Sukumar Rajah: Singapore 50 08/16 02/17 08/17 02/18 08/18 02/19 08/19 02/20 08/20 02/21 08/21 Asset Allocation Discrete Annual Performance in Share Class Currency (%) 08/20 08/19 08/18 08/17 08/16 08/21 08/20 08/19 08/18 08/17 A (acc) EUR-H1 50,51 -1,01 -13,58 -3,55 9,44 Benchmark in USD 53,15 3,00 -7,64 7,12 17,46 % Performance in Share Class Currency (%) Equity 103,05 Cumulative Annualised Cash & Cash Equivalents -3,05 Since Since 1 Mth 3 Mths 6 Mths 1 Yr 3 Yrs 5 Yrs Incept 3 Yrs 5 Yrs Incept A (acc) EUR-H1 7,78 9,87 19,92 50,51 28,75 35,90 46,91 8,79 6,33 6,24 Benchmark in USD 10,94 11,12 22,35 53,15 45,68 83,30 84,41 13,36 12,89 10,11 Calendar Year Performance in Share Class Currency (%) 2020 2019 2018 2017 2016 A (acc) EUR-H1 9,54 4,01 -17,74 34,53 0,74 Benchmark in USD 15,55 7,58 -7,31 38,76 -1,43 Past performance is not an indicator or a guarantee of future performance.
    [Show full text]
  • (15) Sr No Student Name Program Graduated
    5.2.2 Average percentage of placement of outgoing students during the last five years (15) Package in Download Sr No Student Name Program graduated from Name of Employer Lac. Proof 1 Yash Kothari B. Tech (Computer Science and Engineering) Media.net 2995000 Click Here 2 Chavda Vijay Ganpatbhai B. Tech (Computer Science and Engineering) eInfochip 450000 Click Here 3 Shah Shikha Snehal B. Tech (Computer Science and Engineering) Endurance International Group 1400000 Click Here 4 Darshan Kanubhai Darji B. Tech (Computer Science and Engineering) Blue Optima Limited 700000 Click Here 5 Jaydutt Nareshbhai Patel B. Tech (Computer Science and Engineering) Samsung R&D Bangalore 1300000 Click Here 6 Kamiyabali Shabbirali Dedhrotia B. Tech (Computer Science and Engineering) Amazon 2875000 Click Here 7 Rutvik Kartik Sutaria B. Tech (Computer Science and Engineering) Amazon 2875000 Click Here 8 Yash Rasikbhai Sinojiya B. Tech (Computer Science and Engineering) Amazon 2875000 Click Here 9 Khushboo Sanjay Shah B. Tech (Computer Science and Engineering) Deutsche Bank 1430000 Click Here 10 Priyanka Deepak Jiandani B. Tech (Computer Science and Engineering) Deutsche Bank 1430000 Click Here 11 Devam Manish Doshi B. Tech (Computer Science and Engineering) Endurance International Group 1400000 Click Here 12 Bhavan Manoj Prajapati B. Tech (Computer Science and Engineering) Samsung R&D Bangalore 1300000 Click Here 13 Het Shaileshbhai Pandya B. Tech (Computer Science and Engineering) Samsung R&D Bangalore 1300000 Click Here 14 Azhar Ali Khaked B. Tech (Computer Science and Engineering) Canary Mail 1220000 Click Here 15 Dhanin Satish Gupta B. Tech (Computer Science and Engineering) Samsung R&D 1200000 Click Here 16 Haridutt Prakashbhai Jani B.
    [Show full text]
  • BOBCAPS ELIXIR Pharmaceuticals and Healthcare Investment Banking Newsletter Inaugural Edition April – September 2018
    BOBCAPS ELIXIR Pharmaceuticals and Healthcare Investment Banking Newsletter Inaugural Edition April – September 2018 BOB CAPITAL MARKETS LTD. A wholly owned subsidiary of Bank of Baroda President’s Note Inside this Edition Dear Reader, 3 Company News It gives me immense pleasure to share the inaugural edition of BOBCAPS ELIXIR, Investment Banking Newsletter covering Pharmaceuticals and Healthcare sectors. Our endeavour is to 6 Industry News publish ELIXIR as a quarterly newsletter covering the industry deal dynamics, trends and events that has shaped the industry in recent times. 7 Key Transactions We have covered the following key subsectors – Pharmaceuticals, Biotechnology & Life Sciences, Healthcare & Diagnostics and Medical Devices & Consumables. 8 Select Deals – Case Study We hope you find this newsletter interesting and we look forward to receiving your feedback to help us improvise on our future editions. Public Market Data 10 Please get in touch with us: [email protected] Warm Regards, 13 Team Avdhoot Deshpande President, Investment Banking – Equity Company News Product & Regulatory (1/2) Product Launch Glenmark launches Akynzeo in India under licensing pact with Helsinn Glenmark receives US FDA approval for generic Vagifem 10 mcg Glenmark Pharmaceuticals launched Akynzeo, a drug used for prevention of Glenmark Pharmaceuticals Inc, USA (Glenmark) has announced that USFDA has chemotherapy-induced nausea and vomiting, in India and Nepal under an granted final approval for Estradiol Vaginal Inserts USP, 10 mcg, the generic version exclusive licensing pact with Swiss pharma group Helsinn. Akynzeo is an oral fixed of Vagifem, 10 mcg, of Novo Nordisk which is used for providing relief from combination of netupitant (300 mg) and palonosetron (0.5 mg).
    [Show full text]
  • (15) Sr No Student Name Program Graduated
    5.2.2 Average percentage of placement of outgoing students during the last five years (15) Package in Download Sr No Student Name Program graduated from Name of Employer Lac. Proof Water and Sanitation management 1 Patel Devanshi Dharmendrabhai M. Sc. (Microbiology) 204000 Click Here Organisation 2 Vadera Jatin Arvindbhai M. Pharm (Regulatory Affairs) Urja Consumer health care (Velocity) 300000 Click Here 3 Divyanshu Joshi B.B.A., LL.B. (Hons.) Self Employed 470000 Click Here 4 Priyanshi Nagarkoti B.A., LL.B. (Hons.) Self Employed 470000 Click Here 5 Harsh Rathi B.B.A., LL.B. (Hons.) Self Employed 470000 Click Here 6 Jitendra Sharda B. Com., LL.B. (Hons.) Self Employed 470000 Click Here 7 Harshit Chordia B.A., LL.B. (Hons.) Self Employed 470000 Click Here 8 Aditi Singh B.A., LL.B. (Hons.) Chir Amrit 470000 Click Here 9 Shubham Kejriwal B. Com., LL.B. (Hons.) Self Employed 470000 Click Here 10 Shah Vyom Himanshu B. Com., LL.B. (Hons.) Adv. Gautam Joshi 470000 Click Here 11 Shreyans Ranka B. Com., LL.B. (Hons.) Self Employed 470000 Click Here 12 Sarthak Sonwalkar B.A., LL.B. (Hons.) PRS LAMP Fellowship 470000 Click Here 13 Pranav Malhotra B. Com., LL.B. (Hons.) Self Employed 470000 Click Here 14 Prabhansh Sharma B.A., LL.B. (Hons.) Self Employed 470000 Click Here 15 Tanna Raj Sanjay B. Com., LL.B. (Hons.) H L Patel Advocates 470000 Click Here 16 Saransh Sharma B.A., LL.B. (Hons.) Uttar Pradesh Judiciary 470000 Click Here 17 Kunjal Arora B. Com., LL.B.
    [Show full text]
  • Inner 48 Young Citizens' Fund Low
    Tata Young Citizens’ Fund (An open ended fund for investment for children having a lock-in for at least 5 years or till the child attains age of majority (whichever is earlier)) As on 31st July 2020 PORTFOLIO INVESTMENT STYLE Company name No. of Shares Market Value % of Company name No. of Shares Market Value % of An equity-oriented scheme that aims to create long term Rs. Lakhs Assets Rs. Lakhs Assets wealth through quality companies providing long term Equity & Equity Related Total 16430.00 92.45 Healthcare Services growth opportunities. The debt portion aims to generate Auto Ancillaries Narayana Hrudayalaya Ltd. 80000 231.96 1.31 regular income through quality debt securities. MRF Ltd. 770 470.07 2.65 Pesticides INVESTMENT OBJECTIVE Balkrishna Industries Ltd. 25600 338.44 1.90 Bayer Cropscience Ltd. 5900 327.64 1.84 The investment objective of the Scheme is to generate long Banks Petroleum Products term capital growth. However, there is no assurance or guarantee that the investment objective of the Scheme will HDFC Bank Ltd. 145000 1497.56 8.43 Reliance Industries Ltd. 84000 1736.36 9.77 be achieved. The scheme does not assure or guarantee ICICI Bank Ltd. 266000 922.49 5.19 Pharmaceuticals any return. Kotak Mahindra Bank Ltd. 46500 635.07 3.57 Cadila Healthcare Ltd. 140000 543.76 3.06 DATE OF ALLOTMENT Axis Bank Ltd. 63000 271.94 1.53 Dr Reddys Laboratories Ltd. 9600 434.02 2.44 October 14, 1995 Cement Sun Pharmaceutical Industries Ltd. 52000 276.48 1.56 Ultratech Cement Ltd. 4500 185.28 1.04 Divi Laboratories Ltd.
    [Show full text]
  • COMPETITION COMMISSION of INDIA Case No. 68 of 2016 in Re
    COMPETITION COMMISSION OF INDIA Case No. 68 of 2016 In Re: Biocon Limited 20thKM Hosur Road, Electronic City, Bangalore, Karnataka - 560100 Informant No. 1 Mylan Pharmaceuticals Private Limited Plot No. 1-A/2, MIDC Industrial Area, Taloja, Panvel, Raigad (Dist), Maharashtra - 410208 Informant No. 2 And F. Hoffmann-La Roche AG Konzern-Hauptsitz, Grenzacherstrasse 124, CH-4070 Basel, Switzerland Opposite Party No. 1 Genentech Inc. 1 DNA Way, South San Francisco, CA - 94080 Opposite Party No. 2 Roche Products (India) Private Limited 1503, 15thFloor, ‘the Capital’, Plot No. C-70, Behind ICICI Bank, BKC, Bandra (E), Mumbai - 400051 Opposite Party No.3 CORAM Mr. Devender Kumar Sikri Chairperson Mr. S.L. Bunker Member Mr. Sudhir Mital Member Mr. Augustine Peter Member Case No. 68 of 2016 Page 1 of 36 Mr. U.C. Nahta Member Justice G.P. Mittal Member Presence For IP 1 & 2: Mr. Amit Sibal, Senior Advocate Mr. G.R. Bhatia, Advocate Mr. A. Hussain, Advocate Ms. Modhulika Bose, Advocate Mr. Rohan Alva, Advocate Mr. Tamir Siddiqi, Advocate Ms. Kanika Chaudhary Nayar, Advocate Ms. Rishika Taneja, Advocate Ms. Deeksha Manchanda, Advocate Mr. Akhilesh Nand, General Counsel, IP-1 Mr. Bhaskar Sharma, Assistant Manager, IP-1 Mr. Sandeep Rathore, Vice President, IP-2 Ms. Sofiyah Sulaiman, Assistant General Manager, IP-2 For OP-1, 2 & 3: Mr. Ramji Srinivasan, Senior Advocate Mr. Samir Gandhi, Advocate Mr. Rahul Rai, Advocate Mr. N. Mahabir, Advocate Mr. Vishal Gehrana, Advocate Ms. Shivanghi Sukumar, Advocate Ms. Rhea Srivastava, Advocate Mr. Rahul Vartak, Director Patents, OP-3 Mr. Simpson, Director Market Access, OP-3 Mr.
    [Show full text]
  • Chronic Hepatitis C Treatment Expansion: Generic Manufacturing
    CHRONIC HEPATITIS C TREATMENT EXPANSION Generic Manufacturing for Developing Countries Gilead is working to enable access to its medicines for all people who can benefit from them, regardless of where they live or their economic means. Snapshot Gilead has agreements with 11 There are 103 million Gilead also offers its branded Indian companies to manufacture people living with hepatitis C hepatitis C medicines at a generic hepatitis C medicines for in these developing countries significantly reduced flat 101 developing countries price in these countries For more than a decade, Gilead has been working in partnership with governments, healthcare systems, providers, public health entities and generic manufacturers to make its HIV and hepatitis B medicines available worldwide. Currently, 8 million people living with HIV in developing countries receive Gilead antiretroviral medicines through these efforts. Gilead is now working to help ensure broad access to its hepatitis C medicines in developing countries. Gilead has signed agreements with 11 India-based generic pharmaceutical manufacturers to develop sofosbuvir, the single tablet regimen of ledipasvir/sofosbuvir and the investigational single tablet regimen of sofosbuvir/ velpatasvir for distribution in 101 developing countries. Gilead has also signed agreements with three local generic manufacturers for in-country production and distribution of our hepatitis C medicines in Egypt and Pakistan. Generic Agreements Under the licensing agreements, Gilead’s Indian generic manufacturing partners have the right to develop and market generic versions of Gilead HCV medicines in certain developing countries. The generic drug companies may set their own prices and receive a complete technology transfer of the Gilead manufacturing process, enabling them to scale up production as quickly as possible.
    [Show full text]
  • Hpmg Shares & Sec
    Your best guide to financial markets Weekly Research Reports GROWING TOGETHER www.hpmgshares.com HPMG Wealth (weekly) Top Sectors for the Week CONTENTS Title Page No. HPMG Wealth (Weekly) 03-04 Top Sectors for the Week 05-14 Weekly Pivot Table (Equities) 15 Weekly Pivot Table (Commodities) 16 Disclaimer 17 HPMG WEALTH WEEKLY Let Your Money Grow Confidently ! Stock ideas backed by strong research HPMG Wealth Weekly… Getting rich is easy with help of HPMG Wealth Weekly. This weekly research report helps you to identify the best five momentum stocks for the week. ‘Pick of the week’ is best among the mentioned five and is always with detailed ‘Technical & Macro outlook’. The trick to “Get Rich quickly and to Stay Rich forever” is a combination of alertness and awareness. With the right information on stocks from HPMG Wealth Weekly, your money is likely to grow confidently and living the “rich” life, is achievable. GROWING TOGETHER www.hpmgshares.com HPMG WEALTH WEEKLY Monday Let Your Money Grow Confidently ! 21st December, 2020 STOCKS CMP BIAS TRADING/ INVESTMENT STRATEGY Avanti Feeds is the leading manufacturer of shrimp feeds and Shrimp Processor with 45% market share in domestic shrimp feed market. The firm was incorporated in the year 1993 and is now having a market cap of Rs AVANTI FEEDS 550 Positive 7417 Crores. Technically, downside seen well supported at 453-469 zone. Look to buy at CMP, and on dips between 491-495 zone, targeting 587.50/601 and then aggressive targets at 621 mark. Stop below 447. Holding Period: 2-3 Months.
    [Show full text]
  • Sector Update Pharmaceutical Sector
    Institutional Equities Pharmaceutical Sector 29 September 2020 Scenario Analysis for Large cap Pharma – FY21E-24E Vishal Manchanda In the near to medium term (FY21–FY24), earnings growth trajectory for most large cap Research Analyst pharma names in the sector will be driven by timing of monetization of their complex [email protected] generic pipeline and innovation led NCE opportunities in the US. We do a sensitivity +91 9737437148 analysis of these complex generic opportunities / NCE opportunities on the earnings Gaurang Sakare for the large cap companies under our coverage to arrive a bull, base and bear case Research Associate scenario. We estimate the impact of delay or failure to monetize the pipeline on [email protected] potential earnings for these companies – FY21 – FY24. Apart from complex generics, +9122 6273 8093 other elements that can meaningfully influence earnings in the medium term is also the IPM growth and scale up around biosimilar initiatives / successful vaccine approval for select companies. Complex Generic Pipeline is robust for most players and we are in early phase of monetization: In case of Lupin and Cipla, they have a pipeline of respiratory assets that they would look to execute in the US. For Sun pharma, there is lower visibility on the complex generic ANDA pipeline, but scale up of specialty asset is the key earnings driver. The ANDA pipeline of Sun pharma has complex ophthalmic and injectable assets, but the approval timelines remain unknown. Dr. Reddy has multiple assets on the complex generic side which include – gNuvaring, gCopaxone, gVascepa, bRituxan, gRevlimid and gKuvan. Likewise, Biocon, will be focusing on approval for their biosimilar assets –bAvastin and bNovolog, and Sector Update Sector scale up of bLantus in the US.
    [Show full text]
  • Impact of Financial Planning on Financial Performance-A Study of Select Undertakings
    Quest Journals Journal of Research in Business and Management Volume 9 ~ Issue 5 (2021) pp: 88-95 ISSN(Online):2347-3002 www.questjournals.org Research Paper Impact of Financial planning on Financial performance-A study of select undertakings Dr. PasunuriAmaraveni Associate Professor, University College of Commerce & Business Management, Kakatiya University, Warangal, Telangana, (India) MulukalapallySusruth Research scholar, Kakatiya University, Warangal, Telangana (India) ABSTRACT Financial planning is an integral part of financial management which deals with the management of a firm’s funds with a view to maximizing profit and the wealth of shareholders. The main aim of this study is to examine the impact of financial planning on financial performance. The sample used in this study are 5 companies of pharmaceutical industry which listed in National stock exchange and secondary data collected for period 2011- 2020.Regression analysis were employed to analyze the relationship between the dependent variable and independent variables. Findings show that there is a significant relationship between Financial planning and the financial performance with the R2 of 43%,30%,45%,36% and38%. Overall, the financial performance of Alkem laboratories Ltd. is highest with comparison of other companies and lowest is cadila Healthcare Ltd. The study findings indicated that Financial planning had positive impact on the financial performance. The study recommended the pharma companies should invest optimum amount infunding decisions, investment decisions and implementing financial policies with maintaining minimum level of profit as it had positive impact on the financial performance, the least variation to the expected results and that leads to highest contribution to operating profit.The study therefore concludes that sound financial planning by the pharma companies lead to a better financial performance as accountability was enhanced through all levels of decision making.
    [Show full text]
  • MEDICATION GUIDE Deferasirox (Dee Fer' a Sir Ox) Tablets
    MEDICATION GUIDE • people 2 years of age and older who have an increased amount of iron in their blood for a long period of time (chronic), caused by repeated blood transfusions Deferasirox (dee fer’ a sir ox) Tablets • certain people 10 years of age or older with thalassemia who have an increased What is the most important information I should know about deferasirox tablets? amount of iron in their blood but who are not receiving regular blood transfusions Deferasirox tablets can cause serious side effects, including: It is not known if deferasirox tablets is safe and effective when used with other medicines Kidney problems: Deferasirox tablets can cause can cause sudden (acute) kidney to treat an increased amount of iron in the blood. problems, including kidney failure that may require treatment with dialysis, and may cause death. Deaths have happened mostly in people who also have other health It is not known if deferasirox tablets is safe and effective for treating children under 2 problems and had a blood disorder that was in an advanced stage. Adults and children years of age who have an increased amount of iron in their blood for a long period of who already have kidney problems and are taking certain medicines with deferasirox time (chronic) caused by repeated blood transfusions. tablets may also have an increased risk of sudden kidney problems. Be sure to tell your It is not known if deferasirox tablets is safe and effective for treating children under 10 healthcare provider about all the medicines you take during treatment with deferasirox years of age with thalassemia who have an increased amount of iron in their blood, but tablets.
    [Show full text]